Compare KPTI & USEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KPTI | USEG |
|---|---|---|
| Founded | 2008 | 1966 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6M | 39.1M |
| IPO Year | 2013 | N/A |
| Metric | KPTI | USEG |
|---|---|---|
| Price | $6.88 | $0.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $22.17 | $3.50 |
| AVG Volume (30 Days) | 175.7K | ★ 343.9K |
| Earning Date | 11-03-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $142,530,000.00 | $9,484,000.00 |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $3.18 | $57.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.51 | $0.92 |
| 52 Week High | $12.45 | $6.40 |
| Indicator | KPTI | USEG |
|---|---|---|
| Relative Strength Index (RSI) | 62.12 | 38.67 |
| Support Level | $5.99 | $0.92 |
| Resistance Level | $7.48 | $1.01 |
| Average True Range (ATR) | 0.53 | 0.05 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 78.67 | 7.42 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business properties and operations in the Rockies region (Montana, Wyoming, and North Dakota), the Mid-Continent (Oklahoma, Kansas, and North and East Texas), and the West Texas, South Texas, and Gulf Coast regions. The company generates revenue from its interest in the sales of oil and natural gas production. The group operates in the exploration and production segment of the oil and gas industry, onshore in the United States.